Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × OTHER × Tislelizumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 473 Leukemia, Myeloid, Acute 440 Carcinoma, Non-Small-Cell Lung 345 Neoplasms 341 Pancreatic Neoplasms 298 Glioblastoma 288 Precursor Cell Lymphoblastic Leukemia-Lymphoma 285 Multiple Myeloma 283 Melanoma 279 Prostatic Neoplasms 268 Leukemia 265 Brain Neoplasms 257 Lymphoma 248 Neoplasm Metastasis 246 Lung Neoplasms 242 Recurrence 238 Ovarian Neoplasms 230 Lymphoma, Non-Hodgkin 221 Colorectal Neoplasms 214 Leukemia, Lymphocytic, Chronic, B-Cell 209 Glioma 198 Myelodysplastic Syndromes 184 Lymphoma, Large B-Cell, Diffuse 163 Carcinoma, Hepatocellular 157 Lymphoma, Follicular 150 Hodgkin Disease 146 Head and Neck Neoplasms 144 Unspecified Adult Solid Tumor, Protocol Specific 138 Lymphoma, Mantle-Cell 138 Sarcoma 137

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04906044 2023-11-18

STARS-RC03

The First Hospital of Jilin University

Phase 1 Active not recruiting

Gastrointestinal

Tislelizumab

Data powered by HemOnc (CC BY 4.0) Colophon ⚡